Cannabis Company – Aphria Inc. New Joint Distribution Agreement and C$100 Million Capital Raise

Company Overview

Aphria Inc. (OTCQB: APHQF) is a Canadian company that produces, supplies, and sells medical cannabis. Pure Nature Wellness Inc. (PNW), a wholly-owned subsidiary of the company, is licensed to produce and sell medical cannabis under the provisions of the Access to Cannabis for Medical Purposes Regulations (ACMPR).  The company’s greenhouse operations are located in Leamington, Ontario.

The company produces medical cannabis for both retail and wholesale channels. Retail sales occur primarily through Aphria’s online store and telephone orders. Wholesale shipments are sold to other ACMPR-licensed producers.

Production Capabilities

The company’s medical cannabis products consist of dried cannabis and cannabis oil, in a variety of indica, sativa, and hybrid strains. Aphria’s existing ACMPR license allows for 3,600 kilograms of dried cannabis for wholesale, 2,500 kilograms of dried cannabis for retail sales, and 450 kilograms of cannabis oil. Aphria’s gross margin on retail sales is approximately 70 percent. Margins on wholesale shipments are approximately 50 percent.

As a greenhouse producer, Aphria’s production costs are among the lowest in the industry. Below is the company’s 2016 quarterly production cost per gram compared to competitor data pulled from public filings in March, April, or May 2016.

Source: Company Reports

The all-in cost per gram is calculated as cost of sales (excluding fair value adjustments of biological assets) divided by grams sold. Cash cost is the average cost of sales per gram less amortization. Aphria’s lower costs are driven by fertilizer and electrical savings. The company’s fertilizer cost is C$0.005 / L (as compared to competitor fertilizer costs of C$0.22 / L) and electrical cost is C$5.50 / square foot (as compared to C$65.00 / square foot for indoor growers).

Aphria is in the midst of a multi-phase expansion program. Upon completion of Part II, the company expects that annual production capacity will reach 5,500 kilograms of dried cannabis and 9,000 litres of cannabis oil.

Source: Company Presentation

Market Overview

According to data from Arcview Market Research, North American consumers spent $6.7 billion on legal cannabis products in 2016, a 34 percent increase from the prior year. By 2020, this figure could grow to $18 billion.

The most recent available data collected by Health Canada for Canadian medical cannabis consumption is summarized in the table below:

Source: Health Canada


The Canadian government recently introduced Bill C-45 to fully legalize cannabis. Although the exact timeline is uncertain, many expect legalization to occur within the first half of 2018. Medical sales by licensed producers are already legal, but it remains unclear exactly how recreational sales will be regulated.

The proposed legislation does state that licensed producers under the ACMPR will become licensed producers under the new Cannabis Act. Therefore, existing producers with established operations and access to financing, such as Aphria, Organigram, and Canopy Growth, would be well-positioned to capitalize on new market opportunities. However, if the government adopts a free-market approach to the sale and distribution of cannabis, competition among existing producers and new entrants could increase significantly.

Recent Developments

  • On April 13, 2017, Aphria reported its fifth consecutive quarter of profitability. The company also announced that it was increasing its production capacity targets for its expansion program, to 8,000 kilograms for Part II, 22,000 kilograms for Part III, and 75,000 kilograms for Part IV.
  • On April 19, 2017, Aphria announced a joint deal with Tetra Bio-Pharma for the distribution of dried medical cannabis in Quebec and the Maritime provinces. Based on the success of the arrangement, Tetra and Aphria may expand into other provinces. Commercial operations are expected to begin in the summer of 2017, with revenue being recognized shortly thereafter. Tetra and Aphria have already collaborated on the development of PPP001, a prescription drug using dried cannabis.
  • On April 20, 2017, the company announced that it had raised C$100 million in financing, consisting of C$75 million of equity on behalf of a syndicate of underwriters lead by Clarus Securities Inc. and a C$25 million five-year term loan from WFCU Credit Union. The loan bears interest at a rate of 3.95 percent and follows a 15-year amortization schedule. The net proceeds will be allocated equally between Part IV of the company’s expansion plan and working capital needs.

Third-Quarter Earnings Review

Revenue for the quarter ended February 28, 2017, totaled C$5.1 million, a 90 percent increase from the same period one year ago. Gross margin declined slightly from 73.4 percent to 70.0 percent, but was still in line with the company’s target for retail sales. Earnings before interest, taxes, depreciation, and amortization (EBITDA) in the third quarter of 2017 increased to C$1.0 million, more than double the C$0.4 million reported in the third quarter of 2016. As noted above, this was Aphria’s fifth consecutive profitable quarter.

The company did report a C$0.44 increase in the all-in production cost per gram, climbing from C$1.79 in the second quarter of 2017 to $2.23. Increasing production costs were primarily attributable to abnormal weather conditions at the Leamington facility and costs incurred due to the capacity expansion program.

Aphria’s balance sheet remains strong, with C$84.4 million in cash and equivalents and a working capital balance of C$123.1 million. These figures do not account for the recently announced capital raise.

Stock Influences

  • Changes in the company’s cannabis production capacity;
  • Changes to the company’s production costs;
  • Significant new agreements with customers, suppliers, and/or government agencies; and
  • Changes to the company’s capital structure.

Risk Factors

  • The company’s greenhouse operations are subject to weather risks;
  • The company’s shares trade at a substantial premium to both earnings and sales; and
  • Changes in legislation could impact the competitive marketplace.

Stock Performance

As of April 21, 2017, shares of Aphria closed at $4.96, yielding a market capitalization of $619 million. As shown above the share price has followed a generally positive trend in the past 12 months, gaining more than 270 percent. Over the same period, Aphria’s annualized daily volatility was 70 percent. Daily trading volume in the past year ranged from 10,000 to 200,000 shares with an average of 113,000. The last month has been much more active, with an average daily volume of 317,000 shares and nine trading days with volumes greater than 450,000 shares.


Aphria’s low production costs and healthy margins have helped the company achieve several consecutive profitable quarters. Furthermore, the company has a strong balance sheet, and it recently secured additional financing to expand its operations in order to meet growing demand. The tabled legislation from the Canadian government could provide a significant revenue boost as early as 2018, but may lead to additional competitive pressures from new entrants.


About Traders News Source:


Traders News Source recent profiles and track record, 534% in verifiable potential gains for our members on 3 small cap alerts alone!


January 31st, 2017 (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24th, 2017 for gains of 89% within 60 days-


February 6th, 2017- (NASDAQ: SCON) opened at $1.12/share hit a high of $1.80/share within 10 days our member potential gains- 60% –


March 6th, 2017 (OTC: USRM) opened at .035/share and hit over .17/share within 25 days for gains of 385% for our members-


These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So, if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.


We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.


***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Traders” to the phone number “25827” from your cell phone***





Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.


Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Ivan Neilson, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.


This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.


We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.


When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.


17B Disclosure


Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.


PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.


Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.


TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.


The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.


Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.